Search clinical trials for: Key Risk Message

Total 10000 results

Merck Sharp & Dohme LLC

Terminated

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

Melanoma

Australia, Canada, China, United States, Argentina, Austria, Belgium, Brazil, Chile, France, Germany, India, Ireland, Israel, Italy, Japan, New Zealand, South Africa, Spain, Switzerland, United Kingdom, Colombia, Poland, South Korea, Sw... and more
Merck Sharp & Dohme LLC
European Organisation for Research and Treatment of Cancer

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)

Melanoma
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

Melanoma

Canada, United States, Australia, Belgium, Brazil, Chile, France, Germany, Israel, Italy, Japan, Poland, South Africa, Spain, Switzerland, United Kingdom
Bayer
Janssen Research & Development, LLC; RTI Health Solutions

Completed

Patient and Physician Knowledge of Key Safety Messages

Anticoagulation

Germany, United Kingdom, France, Spain
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Not yet recruiting

Messages That Motivate: Communicating Alcohol-Related Breast Cancer Risk to Young Adult Women (MEMO)

Communication | Alcohol | Cancer Prevention | Behavior, Risk | Message Perception

United States

Search clinical trials for: Key Risk Message

This is a preview